Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer

NCT07292207 is registered in ClinicalTrials.gov with Nagoya City University as lead sponsor.

NCT NCT07292207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07292207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer
Lead sponsor
Nagoya City University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 10, 2026
Completion date
August 31, 2031
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, ctdna monitoring